BOSTON, March 24, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (Pink Sheets : SNDY ) is pleased to announce that the Company has strengthened its current line of Laparoscopic surgical instruments in order to better align its product offerings with current global endoscopy market trends.
Solos has focused its R & D efforts into the design and development of new modifications to its endoscopic instrument lines to accommodate the continual advances in Laparoscopic surgical procedures including bile duct reconstruction, laparoscopic adrenalectomy and distal pancreatectomy, amongst a host of other operations and diagnostic applications. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). These advantages include reduced pain due to smaller incisions and hemorrhaging, and shorter recovery time.
According to salisonline.org, the market for endoscopy devices is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.5% from 2009-2015, with growth driven by innovations in endoscopy technology and expansion of indications suitable for endoscopic surgery. The article went on to acknowledge that laparoscopy is the largest segment, contributing 27% to the global endoscopy market and is projected to grow at a CAGR of 8% until 2015, becoming the largest growth opportunity in endoscopy.
"We are highly enthusiastic regarding the prospects for Solos' next generation portfolio of endoscopic and laparoscopic instrumentation, which are expected to provide the opportunity to regain momentum and expand our revenue growth," stated Bob Segersten, President of Solos Endoscopy, Inc.
The Company expects to post its full unaudited financial results for the fiscal year ended December 31, 2010 on the OTC Markets Group website within in the next week.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.